Martin currently holds the position of Global Sr. Medical Director Gene Therapy Platform at Pfizer Rare Diseases.
A pharmacist by training, he began working in research and development during his PhD and later entered Pfizer’s Medical Affairs department.
A keen interest in genetics and hemophilia saw him exposed to gene therapy early on in its evolution, as hemophilia is one of the disease areas where the pioneering approach was first trialed.
Martin has been with Pfizer since 2009 in various of roles on country, regional and global level. He holds a PhD in Pharmaceutics from Freie Universität Berlin and has authored several peer-reviewed articles.